FXH - ETF AI Analysis
Top Page
First Trust Health Care AlphaDEX Fund (FXH)
Rating:69Neutral
Price Target:―
Positive Factors
Recent Performance Momentum
The fund has shown strong recent gains over the past three months and year to date, indicating positive momentum in its strategy.
Broad Health Care Exposure
With many holdings spread across the health care sector, investors get diversified exposure within a single industry rather than relying on just a few companies.
Meaningful Size
The fund manages over a billion dollars in assets, suggesting it has enough scale and investor interest to support stable operations and trading.
Negative Factors
Single-Sector Concentration
Almost all of the ETF’s assets are in health care, so its performance is heavily tied to the fortunes of that one sector.
U.S.-Only Focus
The fund invests almost entirely in U.S. companies, offering little geographic diversification if the U.S. market or health care policy environment weakens.
Above-Average Expense Ratio
The ETF’s expense ratio is relatively high compared with many broad index funds, which means more of the returns are used to cover fees.
FXH vs. SPDR S&P 500 ETF (SPY)
AUM1.02B
RegionNorth America
Expense Ratio0.61%
Beta0.63
IssuerFirst Trust
Inception DateMay 08, 2007
Dividend Yield0.8%
Asset ClassEquity
Index TrackedStrataQuant Health Care Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume53,006
30 Day Avg. Volume41,200
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
144.83Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering74
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FXH Summary
FXH is an exchange-traded fund that focuses on the StrataQuant Health Care Index, giving you broad exposure to U.S. health care companies. It holds a mix of drug makers, medical device firms, and health care service providers, including well-known names like Pfizer and Cigna. Someone might invest in FXH to seek growth from long-term trends such as an aging population and ongoing medical innovation, while also gaining diversification within the health care sector. A key risk is that it is heavily concentrated in health care stocks, so its value can rise or fall sharply with changes in that industry.
How much will it cost me?The expense ratio for FXH is 0.62%, which means you’ll pay $6.20 per year for every $1,000 invested. This is higher than average because FXH is actively managed, using a specialized methodology to select and weight health care stocks for potential outperformance. Actively managed funds typically have higher costs due to the research and strategy involved.
What would affect this ETF?The FXH ETF, focused on the U.S. health care sector, could benefit from ongoing advancements in medical technology, increased demand for health care services due to aging populations, and innovation within its top holdings like biotechnology and pharmaceutical companies. However, it may face challenges from regulatory changes, pricing pressures in the health care industry, and broader economic conditions such as rising interest rates, which could impact growth-focused investments. Its strong exposure to North America provides stability but limits diversification outside the U.S.
FXH Top 10 Holdings
FXH is a pure U.S. health care play, and its story right now is about managed care and services trying to pull biotech and devices along for the ride. DaVita and Centene have been rising steadily, acting like workhorses for the fund, while Axsome Therapeutics adds a more volatile but currently supportive growth edge. On the other side, Boston Scientific and Universal Health have been lagging, sapping some momentum, and big pharma name Pfizer looks more mixed than inspiring. Overall, performance is being driven by health care services rather than the traditional drug giants.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Universal Health | 2.47% | $25.12M | $9.43B | 2.81% | 74 Outperform | |
| Regeneron | 2.46% | $25.08M | $68.78B | 19.43% | 78 Outperform | |
| Zimmer Biomet Holdings | 2.46% | $25.07M | $17.67B | -4.07% | 73 Outperform | |
| Boston Scientific | 2.45% | $25.00M | $65.77B | -57.00% | 79 Outperform | |
| DaVita | 2.44% | $24.90M | $15.12B | 62.62% | 59 Neutral | |
| Cigna | 2.43% | $24.75M | $76.60B | -0.47% | 72 Outperform | |
| Solventum Corporation | 2.40% | $24.45M | $13.51B | 9.08% | 73 Outperform | |
| Pfizer | 2.36% | $24.02M | $139.86B | 1.48% | 74 Outperform | |
| Medline | 2.32% | $23.60M | $50.91B | ― | ― | |
| Centene | 2.30% | $23.40M | $31.31B | 138.57% | 58 Neutral |
FXH Technical Analysis
Positive
―
Price Trends
119.60
Positive
115.27
Positive
114.63
Positive
Market Momentum
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FXH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 124.35, equal to the 50-day MA of 119.60, and equal to the 200-day MA of 114.63, indicating a bullish trend. The MACD of ― indicates undefined momentum. The RSI at ― is undefined, neither overbought nor oversold. The STOCH value of ― is undefined, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FXH.
FXH Peer Comparison
Comparison Results
Performance Comparison
FXH
First Trust Health Care AlphaDEX Fund
128.24
28.50
28.57%
IBB
iShares Biotechnology ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
FHLC
Fidelity MSCI Health Care Index ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
FBT
First Trust NYSE Arca Biotechnology Index Fund
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
DisclaimerThis AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents